New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2013
11:01 EDTNVS, ESI, AFFY, KBR, NRFHigh option volume stocks: NVS ESI AFFY KBR NRF
News For NVS;ESI;AFFY;KBR;NRF From The Last 14 Days
Check below for free stories on NVS;ESI;AFFY;KBR;NRF the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 2, 2014
07:01 EDTNVSNovartis volatility expected to move on heart failure drug LCZ696 study
Subscribe for More Information
August 31, 2014
14:04 EDTNVSWorldwide Business Research to hold a conference
Subscribe for More Information
13:47 EDTNVSNovartis heart failure drug LCZ696 shows superiority to enalapril in study
Subscribe for More Information
12:50 EDTNVSEuropean Society of Cardiology to hold a conference
Subscribe for More Information
August 29, 2014
16:21 EDTNVSOn The Fly: Closing Wrap
Subscribe for More Information
12:23 EDTNVSNovartis drug data to be presented this weekend
Subscribe for More Information
12:18 EDTNVSOn The Fly: Midday Wrap
Subscribe for More Information
11:07 EDTNVSHigh option volume stocks
Subscribe for More Information
10:51 EDTNVSUnited Therapeutics jumps after court rules generic will infringe
United Therapeutics (UTHR) alleged patent infringement against Sandoz, a unit of Novartis (NVS), related to the latter's filing for approval of a generic version of United Therapeutics' remodulin drug. A New Jersey court ruled today that Sandoz's proposed ANDA product will infringe the claims of UTC's '117 patent, according to a court filing. Following the court ruling, shares of United Therapeutics are up 15% to $105.39 in morning trading.
10:17 EDTNVSInnoPharma announces FDA approval of generic Dacogen
Subscribe for More Information
10:04 EDTNVSNovartis hematopoietic support for ALL patients granted orphan status
Novartis' hematopoietic stem and progenitor cells expanded ex-vivo with a low molecular weight aryl hydrocarbon receptor antagonist was granted orphan designation as a hematopoietic support in patients with acute lymphoblastic leukemia, or ALL, the FDA stated. Reference Link
08:46 EDTNVSNovartis has a conference call hosted by JPMorgan
JPMorgan Analyst Vosser hosts a conference call with CEO Joe Jimenez on September 5 at 8 am.
August 28, 2014
08:40 EDTNVSPositive data on Novartis LCZ696 could raise sales outlook, says Leerink
Subscribe for More Information
August 26, 2014
07:25 EDTESIITT Educational has negative read through from Corinthian, says Wells Fargo
Subscribe for More Information
August 25, 2014
08:52 EDTESIITT Educational volatility elevated into Q2 and outlook
Subscribe for More Information
07:23 EDTESIGovernment not looking to push other colleges out of business, says Wells Fargo
In the wake of Corinthian Colleges' (COCO) dissolution due to actions taken by the Department of Education, Wells Fargo thinks the government did not intend for this scenario to unfold. After speaking with unnamed "knowledgeable sources" about the issue, the firm does not expect the department to take similar actions in the future because doing so would create too much of a workload for the department, Wells believes. Publicly traded companies in the space include American Public Education (APEI), Apollo Education (APOL), Bridgepoint Education (BPI), Career Education (CECO), Corinthian Colleges (COCO), DeVry (DV), Grand Canyon (LOPE), ITT Educational (ESI) and Strayer (STRA).
August 21, 2014
08:10 EDTKBRKBR awarded EPC contract for new HDPE facility in La Porte, Texas
KBR announced it has been awarded a contract from Gemini HDPE, a manufacturing joint venture between INEOS Olefins & Polymers USA and Sasol, to provide engineering, procurement, and construction, or EPC, services for a new high-density polyethylene, or HDPE, facility to be located at INEOS's Battleground Manufacturing Complex in La Porte, Texas. The new facility is designed to produce 470 kilotons per annum of bimodal HDPE using Innovene S process technology licensed from INEOS Technologies. The new, single-train facility will include new polymerization, pelletization, and railcar load-out facilities, plus upgrades to existing utilities and infrastructure.
August 20, 2014
12:06 EDTNVSNovartis treatment for pigmented villonodular synovitis gets orphan designation
According to a post on the FDA's website, Novartis' recombinant human monoclonal antibody of the IgG1 kappa class against human macrophage colony-stimulating factor received orphan designation. Reference Link
05:17 EDTNVSNovartis provides drug candidate compounds to TB Alliance
Subscribe for More Information
August 19, 2014
05:11 EDTNVSGamida Cell announces investment, option agreement with Novartis
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use